Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

著者: Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole, Charles G. Drake, Sabina Signoretti, Mahmut Akgül, Nicholas Baniak, Elsa M. Li-Ning, Matthew B. Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Z. Kaimakliotis, Yasser Ged, Phillip M. Pierorazio, E. Jason Abel, Mehmet Asım Bilen, Kenneth Ogan, Helen Moon, Krishna Ramaswamy, Eric A. Singer, Tina Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E. Delacroix, Mark J. Waples, Andrew James, Peng Wang, Toni K. Choueiri, M. Dror Michaelson, Anil Kapoor, Daniel Y.C. Heng, Brian Shuch, Bradley C. Leibovich, Primo N. Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert G. Uzzo, Gennady Bratslavsky, Naomi B. Haas, Michael A. Carducci - The Lancet 2024 被引用: 82